EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 3-Nov-2026 21:16 ET (4-Nov-2026 02:16 GMT/UTC)

Adjuvant immunotherapy shows no survival benefit for NSCLC patients achieving pCR after neoadjuvant treatment

Chinese Medical Journals Publishing House Co., Ltd.
Peer-Reviewed Publication

A real-world study of 145 resectable NSCLC patients who achieved pathological complete response after neoadjuvant chemoimmunotherapy found no significant disease-free or overall survival benefit from adding adjuvant immunotherapy. The findings suggest that patients with a pCR may not need further postoperative treatment, though larger prospective studies are required for confirmation.

Journal: Chinese Medical Journal

Lung tumor microenvironment established by simultaneous activation of KrasG12D and deletion of neddylation conjugation enzyme UBE2M

Science China Press
Peer-Reviewed Publication

A research team led by Prof. Yi Sun at Zhejiang University, reported a unexpected finding that the combination of Kras^G12D activation and genetic inactivation of UBE2M in the lung triggers the cGAS-STING-NF-κB signal to form a inflammatory tumor microenvironment (TME). Mechnistically, Kras^G12D promotes the mitochondrial biogenesis, whereas UBE2M depletion inhibits Parkin neddylation and mitophagy, together causing the cytoplasmic release of damaged mitochondrial DNA. The STING antagonist H-151 rescues TME, indicating a causal role of the cGAS-STING signal. The study therefore demonstrates a unexpected role of UBE2M in prevention TME induced by Kras mutant.

Journal: Science Bulletin

The Josep Carreras Institute joins international effort to advance liquid biopsy research and clinical implementation

Josep Carreras Leukaemia Research Institute
Business Announcement

As a new member of BLOODPAC, a leading international consortium on liquid biopsy, the Josep Carreras Leukaemia Research Institute will contribute to advancing liquid biopsy research and developing standards and validation protocols, with the aim of bringing this knowledge back to the Catalan and Spanish health system.

The Josep Carreras Institute becomes the first Spanish institution to become part of this prominent international consortium, contributing its expertise in blood cancers research to a global network of academic, industry and regulatory stakeholders.

Mini-tumors reveal new drug combinations for liver cancer

University of Basel
Peer-Reviewed Publication

Liver cancer is difficult to treat because tumors vary greatly from patient to patient. Researchers at the University of Basel have captured this diversity by creating a collection of mini-tumors, which they use to systematically search for new treatment options. They tested more than 1,600 compounds using these organoids and used the results to develop promising drug combinations.

Journal: Cell Reports

Brain cancer: Immunotherapy first, surgery afterwards

Université de Genève
Peer-Reviewed Publication

With survival at barely 5% at five years, glioblastoma remains one of the deadliest brain cancers. The first line treatment consists of surgery to remove as much tumour tissue as possible. A team from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) has now shown that this operation triggers a tissue-repair process that makes the residual tumour even harder to combat. By administering lab-engineered immune cells — CAR-T cells — to mice before rather than after surgery, the team achieved unprecedented durable tumour control. This research, with significant clinical implications, is published in the journalNature Communications.

Journal: Nature Communications

Rice bioengineer King joins Texas cancer institute’s AI advisory panel

Rice University
Business Announcement

Michael King, a bioengineering professor at Rice University who focuses on the behavior of cancer and immune cells in the bloodstream, was selected in August as a founding member of a new state advisory committee examining the use of artificial intelligence in cancer research.

Funder: Cancer Prevention and Research Institute of Texas

New imaging technique reveals the inner workings of immune cells

Morgridge Institute for Research
Peer-Reviewed Publication

Doctors use samples of white blood cells taken in clinical settings in lab tests about immune function and for emerging therapies like CAR T cell for certain cancers. But, current tests are limited in scope and sometimes require the addition of molecular labels that make the samples unsuitable for further use or analysis. Investigators at the Morgridge Institute for Research have developed a method of using optical metabolic imaging to identify immune cells and their metabolic state without destroying the samples. The group is working to commercialize this technology and help clinicians get the most out of these commonly used blood samples.

Journal: Biophotonics Discovery

Protein build-up may shape cancer drug response

University of Edinburgh
Peer-Reviewed Publication

The way cancer-causing proteins accumulate in tumours may influence how effectively a promising new generation of medicines can remove them, a study suggests.

Journal: Cell Chemical Biology

Leukemia Research Foundation funds University of Cincinnati research to treat TP53-mutated leukemia

University of Cincinnati
Grant and Award Announcement

The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.

Funder: Leukemia Research Foundation

Breast density laws linked to higher ultrasound use after mammography

Penn State
Peer-Reviewed Publication

Laws that require notification of dense breast tissue following a mammogram and insurance coverage of follow-up imaging were both independently associated with higher ultrasound use after mammography, according to a new study from Penn State College of Medicine.

Journal: JAMA Network Open

71
72
73
74
75